Teva Doubles Down On Alvotech Biosimilars Partnership

Invests $40m, Adds Two More Biosimilars To Deal And Actively Supports Quality Efforts

24 Jul 2023

Teva will get more involved in Alvotech’s quality oversight as part of enhancements to the pair’s US biosimilars collaboration that will also see two products added to the deal, as well as a $40m investment in Alvotech from the Israeli giant.

Cogs with Quality and Manufacturing words — Teva will get more actively involved in Alvotech’s quality processes • Source: Shutterstock

Apparently undaunted by Alvotech’s recent challenges in the US, Teva has made a renewed commitment to its partnership with the Icelandic biosimilars developer that will involve the Israeli firm getting more involved in Alvotech’s manufacturing remediation efforts, as well as making a $40m investment in Alvotech and the pair adding two further biosimilar candidates to their existing partnered portfolio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

What’s Next? Five Things To Look Out For In May

01 May 2025

• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

30 Apr 2025

• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

30 Apr 2025

• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.